Stifel Financial’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$601K Sell
10,207
-475
-4% -$29K ﹤0.01% 2878
2026
Q2
$607K Buy
10,682
+157
+1% +$6.96K ﹤0.01% 2850
2026
Q1
$313K Sell
10,525
-2,235
-18% -$66.8K ﹤0.01% 3154
2025
Q4
$488K Buy
+12,760
New +$415K ﹤0.01% 2873

Other funds holding TVTX

Stifel Financial's TVTX Position: Q3 2026 in Review

Stifel Financial reduced its Travere Therapeutics (TVTX) stake by 4.4% in Q3 2026, selling an estimated $29K and leaving 10,207 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Stifel Financial first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $607K in Q2 2026. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Stifel Financial held 10,207 shares of Travere Therapeutics worth $601K as of Q3 2026.
  • Stifel Financial sold 475 Travere Therapeutics shares in Q3 2026, an estimated $29K.
  • Travere Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q3 2026, its #2878 holding.
  • Stifel Financial first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Stifel Financial's Travere Therapeutics position peaked at $607K in Q2 2026.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.